New trial aims to stop melanoma return after surgery
NCT ID NCT04741997
First seen Oct 31, 2025 · Last updated Apr 30, 2026 · Updated 24 times
Summary
This study is for people with advanced melanoma (stage III or IV) that has a BRAF V600 mutation. Participants first receive a combination of two targeted drugs (encorafenib and binimetinib) before surgery. After surgery, doctors check how much the tumor has responded. Based on that response, participants are randomly assigned to receive additional treatment or not. The goal is to see if this personalized approach lowers the chance of the cancer coming back.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA STAGE III are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
Contact
Contact
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.